Company
Xenon Pharmaceuticals Inc.
XENE · CIK 0001582313
SEC FORM 4CLUSTER · 2 INSIDERS
$1,681,140.00
Purchase of 45,000 shares across 2 reporting persons.
Transaction Code P · Reporting Persons 2
- MORTIMER IAN, PRESIDENT & CEOPurchase of 30,000 shares at $37.38 per share.$1,121,400.00
- Kelly Thomas Patrick, Chief Financial OfficerPurchase of 15,000 shares at $37.316 per share.$559,740.00
Surfaced by rule: 2 distinct insiders, open-market purchases, 7-day window — a deterministic filter, not a recommendation.
Traded Sep 30, 2026 · Disclosed Oct 1, 2026
Source: SEC Form 4 · 0001193125-26-409999 · filed 2026-10-01 · View filing →
Source: SEC Form 4 · 0001193125-26-410001 · filed 2026-10-01 · View filing →
Permalink →
Acquisition (code M) of 5,144 shares at $8.15 per share.
Reporting Person Svoronos Dawn · Transaction Code M
Traded Sep 1, 2026 · Disclosed Sep 3, 2026
Source: SEC Form 4 · 0001193125-26-382412 · filed 2026-09-03 · View filing →
Sale of 6,368 shares at $60.1673 per share.
Reporting Person KENNEY CHRISTOPHER JOHN · Officer Title Chief Medical Officer · Transaction Code S
Traded Aug 28, 2026 · Disclosed Aug 31, 2026
Source: SEC Form 4 · 0001193125-26-377309 · filed 2026-08-31 · View filing →
Sale of 700 shares at $60.9766 per share.
Reporting Person KENNEY CHRISTOPHER JOHN · Officer Title Chief Medical Officer · Transaction Code S
Traded Aug 28, 2026 · Disclosed Aug 31, 2026
Source: SEC Form 4 · 0001193125-26-377309 · filed 2026-08-31 · View filing →
Sale of 10,000 shares at $64.055 per share.
Reporting Person GANNON STEVEN · Transaction Code S
Traded Aug 11, 2026 · Disclosed Aug 13, 2026
Source: SEC Form 4 · 0001193125-26-349351 · filed 2026-08-13 · View filing →